Vir Biotechnology, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 1.10B | 1.62B | 86.18M | 74.20M | 68.56M | -7.6% | |
| Cost of Revenue | (513.87M) | (620.97M) | (572.83M) | (478.64M) | (11.71M) | -97.6% | |
Gross Profit | 581.54M | 994.83M | -486.65M | -404.44M | 56.85M | -114.1% | |
| Operating Expenses | |||||||
| Research & Development | (448.01M) | (474.65M) | (579.72M) | (506.50M) | (432.80M) | -14.6% | |
| Selling, General & Administrative | — | — | — | — | (92.07M) | — | |
| Depreciation & Amortization | (5.81M) | (6.78M) | (19.45M) | (14.56M) | (11.68M) | -19.8% | |
Operating Income (EBIT) | 420.75M | 833.07M | -684.30M | -587.16M | -468.02M | -20.3% | |
| Non-Operating Items | |||||||
| Interest Income | 439.00K | 28.09M | 86.99M | 71.81M | 40.24M | -44.0% | |
| Interest Expense | — | — | — | — | — | — | |
| Other Income/Expenses (Net) | 129.05M | -78.79M | 56.11M | 64.06M | 30.25M | -52.8% | |
Income Before Tax | 549.80M | 754.28M | -628.19M | -523.11M | -437.77M | -16.3% | |
| Income Tax Expense | (21.22M) | (238.44M) | (13.08M) | (1.15M) | (217.00K) | -119.0% | |
Net Income | 528.58M | 515.84M | -615.06M | -521.96M | -437.99M | -16.1% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $4 | $4 | $-5 | $-4 | $-3 | -17.5% | |
| Weighted Avg Shares Outstanding | 129.88M | 132.61M | 134.13M | 136.25M | 138.52M | 1.7% | |
| Weighted Avg Shares Outstanding (Diluted) | 133.44M | 134.81M | 134.13M | 136.25M | 138.52M | 1.7% | |
EBITDA | 555.61M | 761.06M | -641.64M | -508.91M | -426.09M | -16.3% |
Explore VIR
VIR in the Healthcare
Small Cap